Assessing the predictive value of intraductal carcinoma of the prostate (IDC‐P) in determining abiraterone efficacy for metastatic hormone‐sensitive prostate cancer (mHSPC) patients
The Prostate · 2025-02 · 85 (2) · 130-139
DOI: 10.1002/pros.24809 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Prostate, online erschienen am 28.10.2024. Verfasst von Xinyuan Wei und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Androstenes. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Beijing Bethune Charitable Foundation (mnzl202002, mnzl202007), Postdoctoral Research and Development Fund of West China Hospital of Sichuan University (2023HXBH024), Science and Technology Support Program of Sichuan Province (2021YFS0119).
Abstract (Originalsprache)
Background
This study explored the value of intraductal carcinoma of the prostate (IDC‐P) in predicting the efficacy of abiraterone treatment in metastatic hormone‐sensitive prostate cancer (mHSPC) patients.
Methods
A retrospective study of 925 patients who underwent prostate biopsies to detect IDC‐P was conducted, with participants divided into two cohorts. The first cohort of 165 mHSPC patients receiving abiraterone treatment was analyzed to compare therapeutic effectiveness between IDC‐P positive and negative cases. Utilizing propensity score matching (PSM) to reduce bias, outcomes such as PSA response, progression‐free survival (PSA‐PFS), radiographic progression‐free survival (rPFS), and overall survival were assessed. Additionally, the second cohort of 760 mHSPC patients compared the efficacy of abiraterone with conventional hormone therapy, focusing on differences between IDC‐P positive and negative individuals.
Results
After PSM, our first cohort included 108 patients with similar baseline characteristics. Among them, 50% (54/108) were diagnosed with IDC‐P, with 22.2% (12/54) having IDC‐P pattern 1 and 77.8% (42/54) with IDC‐P pattern 2. While no notable difference was seen in PSA responses between IDC‐P positive and negative patients, IDC‐P presence linked to worse clinical outcomes (PSA‐PFS: 18.6 months vs. not reached [NR], p = 0.009; rPFS: 23.6 months vs. NR, p = 0.020). Further analysis showed comparable outcomes for IDC‐P pattern 1 but significantly worse prognosis for IDC‐P pattern 2 (PSA‐PFS: 18.6 months vs. NR, p = 0.002; rPFS: 22.4 months vs. NR, p = 0.010). Subgroup analysis revealed IDC‐P pattern 2 consistently predicted poorer outcomes across patient subgroups. Remarkably, both IDC‐P positive and negative patients gained more from androgen deprivation therapy with abiraterone than conventional treatment, with IDC‐P negative patients showing a more significant survival advantage, supported by better hazard ratios (0.47 and 0.66).
Conclusion
This study found that IDC‐P, especially pattern 2, predicts poor prognosis in mHSPC patients on abiraterone therapy. Also, abiraterone's advantage over hormone therapy is reduced in cases with IDC‐P compared to those without.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China.
- Department of Pathology, West China Hospital, Sichuan University, Chengdu, China.
ORCID-Profile: Xinyuan Wei, Pengfei Shen, Ni Chen, Hao Zeng
Förderung
- Beijing Bethune Charitable Foundation (mnzl202002, mnzl202007)
- Postdoctoral Research and Development Fund of West China Hospital of Sichuan University (2023HXBH024)
- Science and Technology Support Program of Sichuan Province (2021YFS0119)
- Clinical and Translational Medicine Research Project, Chinese Academy of Medical Sciences (2022-12M-C&T-B-098)
- National Natural Science Foundation of China (NSFC 82203110, 82172785, and 81974398)
Zitieren
APA
Wei, X., Zhao, J., Nie, L., Shi, Y., Zhao, F., Shen, Y., Chen, J., Sun, G., Zhang, X., Liang, J., Hu, X., Shen, P., Chen, N., Zeng, H., & Liu, Z. (2025). Assessing the predictive value of intraductal carcinoma of the prostate (IDC‐P) in determining abiraterone efficacy for metastatic hormone‐sensitive prostate cancer (mHSPC) patients. The Prostate, 85(2), 130-139. https://doi.org/10.1002/pros.24809
Vancouver
Wei X, Zhao J, Nie L, Shi Y, Zhao F, Shen Y, et al. Assessing the predictive value of intraductal carcinoma of the prostate (IDC‐P) in determining abiraterone efficacy for metastatic hormone‐sensitive prostate cancer (mHSPC) patients. The Prostate. 2025;85(2):130-139. doi:10.1002/pros.24809
BibTeX
@article{Wei2025,
author = {Wei, Xinyuan and Zhao, Jinge and Nie, Ling and Shi, Yifu and Zhao, Fengnian and Shen, Yu and Chen, Junru and Sun, Guangxi and Zhang, Xingming and Liang, Jiayu and Hu, Xu and Shen, Pengfei and Chen, Ni and Zeng, Hao and Liu, Zhenhua},
title = {Assessing the predictive value of intraductal carcinoma of the prostate (IDC‐P) in determining abiraterone efficacy for metastatic hormone‐sensitive prostate cancer (mHSPC) patients},
journal = {The Prostate},
year = {2025},
volume = {85},
number = {2},
pages = {130--139},
doi = {10.1002/pros.24809}
}
EUVIMED